IIN Inion Oy

RNS Number:0060O
Inion Oy
24 June 2005



24 June 2005



      Inion Expands Biodegradable Medical Implant Product Ranges in Europe

                 CE Mark received for Anchron(TM) Suture Anchor


Tampere, Finland and Takeley, UK. 24 June 2005... Inion (LSE: IIN.L), a rapidly
growing company focused on the development of novel biodegradable medical
implants, has received a CE Mark for the Anchron(TM) Suture Anchor device for
both orthopaedic and sports medicine applications. CE Mark is required by a
number of accredited bodies to medical device manufacturers prior to commercial
distribution in the European Union.


Anchron(TM) is soft tissue repair device that can be used for repairing a range
of injuries, particularly in the shoulder. The system can be used in rotator
cuff and instability repairs surgery such as Bankart and SLAP lesions.


Inion produces a full range of sports medicine devices made from Inion's
proprietary OPTIMA(TM) range of biomaterials, including Hexalon(TM), the world's
first coloured biodegradable repair device for the cruciate ligaments in the
knee; and Trinion(TM), the biodegradable meniscal screw for the repair of torn
knee cartilage. Anchron(TM) now completes the range ensuring that sports
medicine practitioners are able to offer their patients a fully biodegradable
alternative for many common sports injuries.


Dr Auvo Kaikkonen, CEO of Inion commented, "The receipt of this CE Mark and the
completion of our sports medicine offering is an important milestone for Inion.
It will enable the Company to present a compelling product opportunity to
potential distribution partners looking to enhance their own portfolios with a
state-of-the-art technology. "



-Ends-



For further information, please contact:

Inion Oy
Dr Auvo Kaikkonen, Chief Executive Officer             Tel: +358 3 230 6600
Tim Hirst, Corporate Communications                    Tel: +44 (0)1279 874 222


Citigate Dewe Rogerson                                 Tel: +44 (0)20 7638 9571
Mark Swallow / Helena Podd







About Inion (www.inion.com)

Inion Oy is a Finnish company that specialises in the development of
biodegradable medical implants. Inion's core expertise and technology lies in
the design and manufacture of innovative biodegradable plates, screws, pins and
membranes that are used to enhance the healing of skeletal injuries (bone and
soft tissue), such as those caused by trauma or by reconstructive surgery.
Inion's implants are made from its proprietary OPTIMA(TM) family of
biomaterials, with properties tailored for specific surgical applications, in
terms of strength, flexibility and rate of degradation.


Inion has developed and launched products in four strategic business areas -
cranio-maxillofacial surgery, orthopaedic trauma, sports medicine and dental
surgery - in more than 40 countries worldwide, and has a number of international
distribution agreements in place, with among others Stryker Corporation and
Aesculap (part of B.Braun).


Inion was incorporated in early 2000 by an international team of experts in
biodegradable materials and their clinical applications, and listed on the
Official List of the UK Listing Authority in December 2004 (LSE: IIN). The
Company's has corporate headquarters in the UK, R&D and production facilities in
Tampere, Finland, and a US office in Oklahoma City, OK.


This announcement includes "forward-looking statements" which include all
statements other than statements of historical facts, including, without
limitation, those regarding the Group's financial position, business strategy,
plans and objectives of management for future operations (including development
plans and objectives relating to the Group's products), and any statements
preceded by, followed by or that include forward-looking terminology such as the
words "targets", "believes", "estimates", "expects", "aims", "intends", "will",
"can", "may", "anticipates", "would", "should", "could" or similar expressions
or the negative thereof. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors beyond the Group's
control that could cause the actual results, performance or achievements of the
Group to be materially different from future results, performance or
achievements expressed or implied by such forward-looking statements. Such
forward-looking statements are based on numerous assumptions regarding the
Group's present and future business strategies and the environment in which the
Group will operate in the future. Among the important factors that could cause
the Group's actual results, performance or achievements to differ materially
from those in forward-looking statements include those relating to Inion's
funding requirements, regulatory approvals, reliance on third parties,
intellectual property, key personnel and other factors. These forward-looking
statements speak only as at the date of this announcement. The Group expressly
disclaims any obligation or undertaking to disseminate any updates or revisions
to any forward-looking statements contained in this announcement to reflect any
change in the Group's expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based. As a result
of these factors, prospective investors are cautioned not to rely on any
forward-looking statement.












                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCGCGDLUDDGGUS

Inion Oy (LSE:IIN)
Historical Stock Chart
From Jun 2024 to Jul 2024

Inion Oy (LSE:IIN)
Historical Stock Chart
From Jul 2023 to Jul 2024